We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Biosite and FivePrime Announce Antibody Collaboration
News

Biosite and FivePrime Announce Antibody Collaboration

Biosite and FivePrime Announce Antibody Collaboration
News

Biosite and FivePrime Announce Antibody Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Biosite and FivePrime Announce Antibody Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Biosite® Incorporated and Five Prime Therapeutics, Inc. have entered into collaboration for the evaluation of disease targets for potential commercialization of diagnostic and therapeutic products.

Under the collaboration, FivePrime will provide Biosite access to selected functional disease targets for use in developing diagnostics.

In exchange, Biosite will provide FivePrime with Omniclonal® antibodies for selected targets to accelerate FivePrime's therapeutic research efforts.

Biosite's proprietary antibody development process is designed to generate diverse libraries of Omniclonal antibodies with high affinity and low cross-reactivity.

"FivePrime's comprehensive protein discovery program is providing a wealth of valuable therapeutic and diagnostic candidates," commented Gail Maderis, FivePrime's president and chief executive officer.

"This collaboration is a strategic win for both companies. It expands Biosite's portfolio of novel diagnostic targets and provides high quality antibodies to accelerate development of FivePrime's therapeutic pipeline."

"Biosite's discovery efforts are focused on developing a broad and diverse portfolio of novel diagnostics for diseases that lack rapid, accurate diagnostic methods," said Gunars Valkirs, Ph.D., senior vice president Biosite Discovery.

"FivePrime is a recognized industry leader in the discovery of novel targets, so we are pleased to begin this collaboration."

Advertisement